| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_de2076d9a31cb72c082bf1aec6a0ce30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2007-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e29677d06cf6f61105286e1c3b5bb27e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6f7adbfeec28c88590116c8d4d66b6f |
| publicationDate |
2009-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
MX-2008009977-A |
| titleOfInvention |
INSULIN TYPE GROWTH FACTOR RECEIVER ANTAGONISTS (IGF-IR) AS ASSISTANTS FOR PROSTATE CANCER TREATMENT. |
| abstract |
The present invention relates to a method for treating prostate cancer with androgen deprivation therapy and an insulin-like growth factor receptor (IGF-IR) antagonist: Although the rate of response of prostate cancer to therapy Androgen deprivation (ADT) is high, cancer cells that invariably become independent of androgen (AI) and follow tumor growth. The invention inhibits or delays the transition from androgen-dependent cancer to androgen-independent cancer, significantly reduces the risk of recurrence, and improves the treatment outcome. |
| priorityDate |
2006-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |